New drug combo for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new two-drug combination (sacituzumab tirumotecan and envafolimab) for people with advanced bile duct or gallbladder cancer that has already been treated with immunotherapy plus chemotherapy. It aims to see if these drugs can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced bile duct or gallbladder cancer that has grown after trying immunotherapy plus chemotherapy
- Your tumor tests positive (2+ or 3+) for a protein called TROP2
- You are able to do most daily activities on your own (ECOG 0 or 1)
- Your kidneys, liver, and blood counts are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced biliary tract cancer that has stopped responding to previous treatments. It works by targeting a protein called TROP2 on cancer cells. This may be an option if your cancer has progressed and you meet the health criteria.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a combination of treatments for people with bile duct or gallbladder cancer that cannot be removed by surgery. It uses a procedure to burn the tumor (radiofrequency ablation) along with two drugs: one that boosts your immune system and one that targets blood vessels feeding the cancer.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Hear when a new Advanced Biliary Tract Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.